Subtype
Malignant Urinary System Neoplasm
CI-CAN-00001187Explore in graph →
887 active trials28 approved drugs109 evidence items
- NCIt
- C9297
Loading cancer entity…
Subtype
CI-CAN-00001187Explore in graph →
Clinical trials
3,851 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (556)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05252585 | A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML) | active not recruiting | Phase 4 | 4 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06394570 | Enfortumab Vedotin and Stereotactic Radiation for Localized, Cisplatin Ineligible Muscle Invasive Bladder Cancer(STAR-EV) | recruiting | Phase 1 / Phase 2 | 19 | University of Texas Southwestern Medical CenterOTHER |
| 1 |
| Sep 17, 2026 |
| clinicaltrials |
| NCT06733363 | A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer | recruiting | Phase 2 | 344 | Roswell Park Cancer InstituteOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06916624 | Multicenter Study of 18F-Labeled NY104 for PET/CT Imaging in Renal Cell Carcinoma | recruiting | — | 120 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07043972 | Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma | recruiting | Phase 2 | 55 | Fox Chase Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07049926 | Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03) | recruiting | Phase 1 / Phase 2 | 140 | Merck Sharp & Dohme LLCINDUSTRY | 8 | Sep 17, 2026 | clinicaltrials |
| NCT07172802 | A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 102 | GI Innovation, Inc.INDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07227415 | Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer | recruiting | Phase 1 / Phase 2 | 224 | PfizerINDUSTRY | 6 | Sep 17, 2026 | clinicaltrials |
| NCT07297667 | GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours | recruiting | Phase 1 | 30 | Canadian Cancer Trials GroupNETWORK | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07332351 | Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial(TRIFECTA) | not yet recruiting | Phase 2 | 33 | University of WashingtonOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07576725 | Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial | not yet recruiting | Phase 2 | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07667335 | Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer | recruiting | Phase 1 / Phase 2 | 27 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT00050752 | Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer | recruiting | — | 1,130 | National Cancer Institute (NCI)NIH | 1 | Sep 16, 2026 | clinicaltrials |
| NCT01352962 | Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors | completed | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Sep 16, 2026 | clinicaltrials |
| NCT02974738 | A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) | active not recruiting | Phase 1 | 120 | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 0 | Sep 16, 2026 | clinicaltrials |
| NCT04467021 | Cancer and Blood Pressure Management, CARISMA Study | active not recruiting | N/A | 61 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04579224 | Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer | active not recruiting | Phase 3 | 184 | National Cancer Institute (NCI)NIH | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04940299 | Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma | active not recruiting | Phase 2 | 35 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05155033 | Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma | recruiting | Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05319015 | Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus | recruiting | Phase 2 | 30 | University of Texas Southwestern Medical CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05796375 | Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance(ReplaceCysto) | recruiting | Phase 2 | 240 | White River Junction Veterans Affairs Medical CenterFED | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05831891 | Fruquintinib Plus Serplulimab as First-Line Therapy for Metastatic Non-Clear Cell Renal Cell Carcinoma | active not recruiting | Phase 2 | 40 | RenJi HospitalOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05889195 | Detection and Risk Stratification in Veterans Presenting With Microscopic Hematuria(microDRIVE) | active not recruiting | — | 1,000 | Pacific Edge LimitedINDUSTRY | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07297160 | CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors(CALySSEY) | withdrawn | Phase 1 | 0 | Baylor College of MedicineOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07532902 | A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer | recruiting | Phase 1 | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07822373 | A Phase 2 Study Evaluating Bladder Preservation With Enfortumab Vedotin Plus Pembrolizumab in Patients With Muscle-Invasive Urothelial Cancer(PRESERVE) | not yet recruiting | Phase 2 | 25 | University of UtahOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04969315 | TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma | recruiting | Phase 1 / Phase 2 | 35 | Portage BiotechINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05494411 | Named Patient Program for Mitomycin for Pyelocalyceal Solution | available | — | — | UroGen Pharma Ltd.INDUSTRY | 0 | Sep 15, 2026 | clinicaltrials |
| NCT05538663 | Intravesical BCG vs GEMDOCE in NMIBC(BRIDGE) | active not recruiting | Phase 3 | 870 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05863351 | Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study | active not recruiting | Phase 3 | 472 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07217171 | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas | recruiting | Phase 1 | 160 | EvolveImmune United, IncINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07341737 | SL-28 for Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 60 | Second Life TherapeuticsINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07777848 | A Study to Evaluate the Efficacy and Safety of RAG-01 as Monotherapy and in Combination With Chemotherapy in Patients With Non-muscle Invasive Bladder Cancer (NMIBC). | not yet recruiting | Phase 2 | 114 | Ractigen Therapeutics.OTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07820566 | Development of a Preclinical 3D Vascularized and Perfused Tumoroid Model in Oncology and Urology Developed From Patient Tumors (Kidney, Bladder, and Prostate Cancers)(3DBlood) | recruiting | — | 100 | University Hospital, Strasbourg, FranceOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07821177 | Bladder Preservation or Cystectomy for MIBC | active not recruiting | Early Phase 1 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT02812420 | Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery | active not recruiting | Early Phase 1 | 54 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04140526 | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC(PRESERVE-001) | active not recruiting | Phase 1 / Phase 2 | 733 | OncoC4, Inc.INDUSTRY | 2 | Sep 14, 2026 | clinicaltrials |
| NCT04977453 | GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 317 | GI Innovation, Inc.INDUSTRY | 2 | Sep 14, 2026 | clinicaltrials |
| NCT05012371 | Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer | active not recruiting | Phase 2 | 90 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05014139 | A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) | terminated | Phase 1 | 37 | Astellas Pharma Global Development, Inc.INDUSTRY | 6 | Sep 14, 2026 | clinicaltrials |
| NCT05059444 | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation(ORACLE) | recruiting | — | 2,285 | Guardant Health, Inc.INDUSTRY | 5 | Sep 14, 2026 | clinicaltrials |
| NCT05858736 | Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors(PRESERVE-009) | completed | Phase 1 | 18 | OncoC4, Inc.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06500455 | Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain | active not recruiting | Phase 3 | 274 | NRG OncologyOTHER | 4 | Sep 14, 2026 | clinicaltrials |
| NCT06503614 | A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer(ENHANCE) | recruiting | Phase 2 | 60 | John SfakianosOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06722807 | ClAmpless, Sutureless PartIAl Nephrectomy for Renal Masses(CASPIAN) | suspended | N/A | 59 | University of FloridaOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07038928 | TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian Federation(RIVERS) | recruiting | — | 600 | AstraZenecaINDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07516366 | Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial | recruiting | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07527637 | Risk of Scrotal Hydroceles After Nephrectomy For Kidney Cancer | active not recruiting | — | 40,000 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 0 | Sep 14, 2026 | clinicaltrials |
| NCT07643519 | Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma | not yet recruiting | Phase 2 | 39 | University of FloridaOTHER | 0 | Sep 14, 2026 | clinicaltrials |
| NCT07816770 | MANTIS-RCC: Toripalimab-Axitinib Induction in TLS-Positive Advanced Non-Clear Cell and Renal Medullary Carcinomas(MANTIS-RCC) | not yet recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 0 | Sep 14, 2026 | clinicaltrials |
Data updated 12 days agoSource updated Sep 17, 2026source: clinicaltrials